Morgan Stanley’s PharMerica Corporation PMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-178,806
Closed -$5.24M 6817
2017
Q3
$5.24M Sell
178,806
-96,745
-35% -$2.71M ﹤0.01% 2917
2017
Q2
$7.23M Buy
275,551
+124,282
+82% +$3.06M ﹤0.01% 2470
2017
Q1
$3.54M Buy
151,269
+30,407
+25% +$750K ﹤0.01% 3242
2016
Q4
$3.04M Buy
120,862
+87,997
+268% +$2.22M ﹤0.01% 3522
2016
Q3
$922K Sell
32,865
-198,262
-86% -$5.08M ﹤0.01% 4097
2016
Q2
$5.7M Buy
231,127
+181,311
+364% +$4.5M ﹤0.01% 2492
2016
Q1
$1.1M Sell
49,816
-145,666
-75% -$3.88M ﹤0.01% 3860
2015
Q4
$6.84M Buy
195,482
+100,422
+106% +$3.15M ﹤0.01% 2358
2015
Q3
$2.71M Buy
95,060
+78,000
+457% +$2.62M ﹤0.01% 3225
2015
Q2
$568K Sell
17,060
-11,077
-39% -$340K ﹤0.01% 4628
2015
Q1
$793K Sell
28,137
-50,966
-64% -$1.27M ﹤0.01% 4310
2014
Q4
$1.64M Buy
79,103
+1,642
+2% +$39K ﹤0.01% 3731
2014
Q3
$1.89M Sell
77,461
-6,181
-7% -$164K ﹤0.01% 3484
2014
Q2
$2.39M Buy
83,642
+37,425
+81% +$1.04M ﹤0.01% 3341
2014
Q1
$1.29M Buy
46,217
+23,682
+105% +$581K ﹤0.01% 3785
2013
Q4
$484K Sell
22,535
-5,040
-18% -$91.6K ﹤0.01% 4472
2013
Q3
$365K Sell
27,575
-61,732
-69% -$832K ﹤0.01% 4542
2013
Q2
$1.24M Buy
+89,307
New +$1.27M ﹤0.01% 3539

Morgan Stanley's PMC Position: Q4 2017 in Review

Morgan Stanley sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 178,806 shares — an estimated $5.24M sold.

Morgan Stanley first reported a position in PMC in Q2 2013 and held it in 18 quarters. The position peaked at $7.23M in Q2 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.

  • Morgan Stanley reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
  • Morgan Stanley sold 178,806 PharMerica Corporation shares in Q4 2017, an estimated $5.24M.
  • Morgan Stanley first reported a position in PharMerica Corporation in Q2 2013 and held it in 18 quarters.
  • Morgan Stanley's PharMerica Corporation position peaked at $7.23M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.

Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.